CL2014001205A1 - Compuestos derivados de purina, sus sales y solvatos farmaceuticamente aceptables; composicion farmaceutica que los comprende, util para el tratamiento de un trastorno en el que interviene la modulacion de tlr7, tal como infecciones viricas, trastornos inmunitarios o inflamatorios. - Google Patents
Compuestos derivados de purina, sus sales y solvatos farmaceuticamente aceptables; composicion farmaceutica que los comprende, util para el tratamiento de un trastorno en el que interviene la modulacion de tlr7, tal como infecciones viricas, trastornos inmunitarios o inflamatorios.Info
- Publication number
- CL2014001205A1 CL2014001205A1 CL2014001205A CL2014001205A CL2014001205A1 CL 2014001205 A1 CL2014001205 A1 CL 2014001205A1 CL 2014001205 A CL2014001205 A CL 2014001205A CL 2014001205 A CL2014001205 A CL 2014001205A CL 2014001205 A1 CL2014001205 A1 CL 2014001205A1
- Authority
- CL
- Chile
- Prior art keywords
- tlr7
- solvates
- immune
- modulation
- useful
- Prior art date
Links
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 title 2
- 208000036142 Viral infection Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000026278 immune system disease Diseases 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 239000012453 solvate Substances 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11188511 | 2011-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014001205A1 true CL2014001205A1 (es) | 2014-08-01 |
Family
ID=47178000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014001205A CL2014001205A1 (es) | 2011-11-09 | 2014-05-08 | Compuestos derivados de purina, sus sales y solvatos farmaceuticamente aceptables; composicion farmaceutica que los comprende, util para el tratamiento de un trastorno en el que interviene la modulacion de tlr7, tal como infecciones viricas, trastornos inmunitarios o inflamatorios. |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US9556176B2 (enExample) |
| EP (1) | EP2776439B1 (enExample) |
| JP (1) | JP6349256B2 (enExample) |
| KR (1) | KR102025276B1 (enExample) |
| CN (2) | CN104066733A (enExample) |
| AU (1) | AU2012334127B2 (enExample) |
| BR (2) | BR112014011162A2 (enExample) |
| CA (1) | CA2850448C (enExample) |
| CL (1) | CL2014001205A1 (enExample) |
| CY (1) | CY1121452T1 (enExample) |
| DK (1) | DK2776439T3 (enExample) |
| EA (2) | EA036645B1 (enExample) |
| ES (1) | ES2690082T3 (enExample) |
| HR (1) | HRP20181497T1 (enExample) |
| HU (1) | HUE040541T2 (enExample) |
| IL (1) | IL232046A (enExample) |
| IN (1) | IN2014MN00862A (enExample) |
| LT (1) | LT2776439T (enExample) |
| MX (1) | MX347596B (enExample) |
| MY (1) | MY173422A (enExample) |
| PH (1) | PH12014501045B1 (enExample) |
| PL (1) | PL2776439T3 (enExample) |
| PT (1) | PT2776439T (enExample) |
| RS (1) | RS57851B1 (enExample) |
| SG (1) | SG11201401244TA (enExample) |
| SI (1) | SI2776439T1 (enExample) |
| SM (1) | SMT201800514T1 (enExample) |
| UA (1) | UA116083C2 (enExample) |
| WO (1) | WO2013068438A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ593110A (en) | 2008-12-09 | 2013-06-28 | Gilead Sciences Inc | pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS |
| MY170941A (en) | 2011-04-08 | 2019-09-19 | Janssen Sciences Ireland Uc | Pyrimidine derivatives for the treatment of viral infections |
| IN2014MN00862A (enExample) | 2011-11-09 | 2015-04-17 | Janssen R & D Ireland | |
| AU2013288600B2 (en) | 2012-07-13 | 2017-06-29 | Janssen Sciences Ireland Uc | Macrocyclic purines for the treatment of viral infections |
| MX365114B (es) | 2012-10-10 | 2019-05-23 | Janssen Sciences Ireland Uc | Derivados pirrolo[3,2-d]pirimidinicos para el tratamiento de infecciones viricas y otras enfermedades. |
| MY171115A (en) | 2012-11-16 | 2019-09-26 | Janssen Sciences Ireland Uc | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
| UA118751C2 (uk) | 2013-02-21 | 2019-03-11 | ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі | Похідні 2-амінопіримідину для лікування вірусних інфекцій |
| ES2625456T3 (es) | 2013-03-29 | 2017-07-19 | Janssen Sciences Ireland Uc | Desazapurinonas macrocíclicas para el tratamiento de infecciones víricas |
| JP6377139B2 (ja) | 2013-05-24 | 2018-08-22 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染症およびさらなる疾患の処置のためのピリドン誘導体 |
| PL3030563T3 (pl) | 2013-06-27 | 2018-01-31 | Janssen Sciences Ireland Uc | Pochodne pirolo [3,2-d] pirymidyny do leczenia zakażeń wirusowych i innych chorób |
| EP3027624B1 (en) | 2013-07-30 | 2018-09-12 | Janssen Sciences Ireland UC | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections |
| GB201321737D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| EA201790024A1 (ru) | 2014-07-11 | 2017-07-31 | Джилид Сайэнс, Инк. | Модуляторы toll-подобных рецепторов для лечения вич |
| US9738646B2 (en) | 2014-09-16 | 2017-08-22 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
| WO2016087665A2 (en) * | 2014-12-05 | 2016-06-09 | Centre National De La Recherche Scientifique (Cnrs) | Compounds for treating cystic fibrosis |
| MX393198B (es) | 2015-05-08 | 2025-03-19 | Hoffmann La Roche | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas |
| GB201509893D0 (en) * | 2015-06-08 | 2015-07-22 | Ucb Biopharma Sprl | Therapeutic agents |
| SG11201811448RA (en) | 2016-07-01 | 2019-01-30 | Janssen Sciences Ireland Unlimited Co | Dihydropyranopyrimidines for the treatment of viral infections |
| EA038646B1 (ru) | 2016-09-29 | 2021-09-28 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний |
| US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
| US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
| US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
| US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
| US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
| EP3752505B1 (en) | 2018-02-12 | 2023-01-11 | F. Hoffmann-La Roche AG | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
| TW202415645A (zh) | 2018-03-01 | 2024-04-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | ２，４－二胺基喹唑啉衍生物及其醫學用途 |
| US11485741B2 (en) | 2018-04-24 | 2022-11-01 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (TLR7) agonists |
| US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| MX2021009496A (es) | 2019-02-08 | 2021-09-08 | Progeneer Inc | Complejo de colesterol-agonista del receptor 7 u 8 tipo larga distancia, y uso del mismo. |
| LT3952995T (lt) | 2019-04-12 | 2023-11-10 | Riboscience Llc | Bicikliniai heteroarilo dariniai kaip ektonukleotidų pirofosfatazės fosfodiesterazės 1 inhibitoriai |
| CN115151548A (zh) | 2020-01-27 | 2022-10-04 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
| US20230127326A1 (en) | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| US20230131192A1 (en) | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| EP4097106A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| US20230122249A1 (en) | 2020-01-27 | 2023-04-20 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| KR20220132590A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| KR20220132594A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| JP2023512208A (ja) | 2020-01-27 | 2023-03-24 | ブリストル－マイヤーズ スクイブ カンパニー | トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物 |
| WO2021154661A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| WO2021177679A1 (ko) | 2020-03-02 | 2021-09-10 | 성균관대학교산학협력단 | 병원균 외벽 성분 기반 생병원체 모방 나노 입자 및 그 제조 방법 |
| EP4194006A4 (en) | 2020-08-04 | 2024-12-04 | Progeneer Inc. | mRNA VACCINE WITH AN ADJUVANT CAPABLE OF KINETIC CONTROL |
| US20230355750A1 (en) | 2020-08-04 | 2023-11-09 | Progeneer Inc. | Kinetically acting adjuvant ensemble |
| JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2610889B2 (ja) | 1987-09-03 | 1997-05-14 | 日本臓器製薬株式会社 | 新規架橋アデニン誘導体 |
| WO1998001448A1 (en) | 1996-07-03 | 1998-01-15 | Japan Energy Corporation | Novel purine derivatives |
| CA2263566C (en) | 1996-08-28 | 2003-09-09 | Pfizer Inc. | Substituted 6,5-hetero-bicyclic derivatives |
| CN1083841C (zh) | 1996-10-04 | 2002-05-01 | 杏林制药株式会社 | 吡唑并吡啶基哒嗪酮衍生物及其制备方法 |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| US6339089B2 (en) | 1997-08-13 | 2002-01-15 | Fujirebio Inc. | Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same |
| CA2311742C (en) | 1997-11-28 | 2009-06-16 | Sumitomo Pharmaceuticals Co., Ltd. | 6-amino-9-benzyl-8-hydroxypurine derivatives |
| TW572758B (en) * | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
| US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| CA2321153A1 (en) | 1998-02-17 | 1999-08-19 | Timothy D. Cushing | Anti-viral pyrimidine derivatives |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| JP4315300B2 (ja) | 1998-08-10 | 2009-08-19 | 大日本住友製薬株式会社 | 新規なキナゾリン誘導体 |
| JP4342007B2 (ja) | 1998-08-10 | 2009-10-14 | 大日本住友製薬株式会社 | キナゾリン誘導体 |
| DE69917469T2 (de) | 1998-08-27 | 2005-05-12 | Sumitomo Pharmaceuticals Co., Ltd. | Pyrimidin derivate |
| US6583148B1 (en) | 1999-04-08 | 2003-06-24 | Krenitsky Pharmaceuticals, Inc. | Neurotrophic substituted pyrimidines |
| US6503908B1 (en) | 1999-10-11 | 2003-01-07 | Pfizer Inc | Pharmaceutically active compounds |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| WO2003055890A1 (en) | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| TW200407143A (en) | 2002-05-21 | 2004-05-16 | Bristol Myers Squibb Co | Pyrrolotriazinone compounds and their use to treat diseases |
| US7091232B2 (en) | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| WO2003104230A1 (ja) | 2002-06-07 | 2003-12-18 | 協和醱酵工業株式会社 | 二環性ピリミジン誘導体 |
| NZ539064A (en) | 2002-09-27 | 2007-09-28 | Dainippon Sumitomo Pharma Co | Novel adenine compound and use thereof |
| US8455458B2 (en) | 2002-10-16 | 2013-06-04 | Arthrodynamic Technologies, Animal Health Division, Inc. | Composition and method for treating connective tissue damage |
| MXPA05013922A (es) | 2003-06-20 | 2006-02-24 | Coley Pharm Group Inc | Antagonistas de receptor tipo toll de molecula pequena. |
| CA2537450C (en) | 2003-09-05 | 2012-04-17 | Anadys Pharmaceuticals, Inc. | Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus |
| ES2563952T3 (es) | 2004-03-26 | 2016-03-16 | Sumitomo Dainippon Pharma Co., Ltd. | Compuesto de 8-oxoadenina 9-sustituido |
| EP1728792A4 (en) | 2004-03-26 | 2010-12-15 | Dainippon Sumitomo Pharma Co | 8-OXOADENINE COMPOUND |
| WO2007084413A2 (en) | 2004-07-14 | 2007-07-26 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| KR100694123B1 (ko) | 2004-07-30 | 2007-03-12 | 삼성전자주식회사 | 동영상 데이터와 어플리케이션 프로그램이 기록된 저장매체 및 그 재생 장치 및 방법 |
| EP1797050B1 (en) | 2004-08-10 | 2013-10-23 | Janssen Pharmaceutica NV | Hiv inhibiting 1.2.4-triazin-6-one derivates |
| MX2007005408A (es) | 2004-11-09 | 2007-05-16 | Hoffmann La Roche | Compuestos de aminoquinazolinas. |
| US7498409B2 (en) | 2005-03-24 | 2009-03-03 | Schering Corporation | Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists |
| KR20080006004A (ko) | 2005-05-04 | 2008-01-15 | 화이자 리미티드 | 암 및 ｃ형 간염과 같은 바이러스 감염의 치료를 위한톨-유사 수용체 조절제인 2-아미도-6-아미노-8-옥소퓨린유도체 |
| AR054122A1 (es) | 2005-05-12 | 2007-06-06 | Tibotec Pharm Ltd | Pirido[2,3-d]pirimidas utiles como inhibidores de hcv, y metodos para la preparacion de las mismas |
| US7994360B2 (en) | 2005-05-16 | 2011-08-09 | Xtl Biopharmaceuticals Ltd. | Benzofuran compounds |
| CA2619919C (en) | 2005-09-01 | 2014-04-01 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| EP1939198A4 (en) * | 2005-09-22 | 2012-02-15 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
| US20070099941A1 (en) | 2005-11-02 | 2007-05-03 | Cytovia, Inc. | N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| US20090182140A1 (en) | 2005-12-02 | 2009-07-16 | Mitsubishi Tanabe Pharma Corporation | Alicyclic Heterocyclic Compound |
| AU2007216247A1 (en) * | 2006-02-17 | 2007-08-23 | Pfizer Limited | 3 -deazapurine derivatives as TLR7 modulators |
| WO2008009077A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections |
| US9259426B2 (en) | 2006-07-20 | 2016-02-16 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| WO2008073785A2 (en) | 2006-12-07 | 2008-06-19 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| EP2121707B1 (en) | 2006-12-20 | 2012-12-05 | Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. | Antiviral indoles |
| HUE025555T2 (en) | 2007-02-07 | 2016-02-29 | Univ California | Conjugates and applications of synthetic tlr agonists |
| JP2008222557A (ja) | 2007-03-08 | 2008-09-25 | Kotobuki Seiyaku Kk | ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物 |
| WO2008114008A1 (en) * | 2007-03-19 | 2008-09-25 | Astrazeneca Ab | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators |
| JPWO2008114819A1 (ja) | 2007-03-20 | 2010-07-08 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
| AR065784A1 (es) | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| EP2152674B1 (en) | 2007-05-22 | 2011-08-03 | Boehringer Ingelheim International GmbH | Benzimidazolone chymase inhibitors |
| CA2691444C (en) | 2007-06-29 | 2016-06-14 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
| EA201000201A1 (ru) | 2007-08-10 | 2010-12-30 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Азотсодержащие бициклические химические вещества для лечения вирусных инфекций |
| EP2190826A2 (en) | 2007-08-28 | 2010-06-02 | Irm Llc | 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors |
| WO2009030998A1 (en) | 2007-09-05 | 2009-03-12 | Coley Pharmaceutical Group, Inc. | Pyrimidine compounds as toll-like receptor (tlr) agonists |
| PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
| AU2008339917B2 (en) | 2007-12-24 | 2013-02-07 | Tibotec Pharmaceuticals | Macrocyclic indoles as hepatitis C virus inhibitors |
| US20090202626A1 (en) | 2008-02-07 | 2009-08-13 | Carson Dennis A | Treatment of bladder diseases with a tlr7 activator |
| EP2271345B1 (en) | 2008-04-28 | 2015-05-20 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| US9081591B2 (en) | 2008-06-27 | 2015-07-14 | Kyocera Corporation | User interface generation apparatus |
| US8946239B2 (en) | 2008-07-10 | 2015-02-03 | Duquesne University Of The Holy Spirit | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof |
| UY31982A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas |
| AU2010250923A1 (en) | 2009-05-21 | 2011-11-17 | Astrazeneca Ab | Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases |
| TWI468402B (zh) | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β－類澱粉生成之化合物 |
| US8637525B2 (en) | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| EP2491033A4 (en) | 2009-10-20 | 2013-03-13 | Eiger Biopharmaceuticals Inc | AZAINDAZOLES FOR THE TREATMENT OF FLAVIVIRIDAE VIRUS INFECTION |
| CA2777824C (en) * | 2009-10-22 | 2016-11-29 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
| KR101094446B1 (ko) | 2009-11-19 | 2011-12-15 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노［3,2-ｄ］피리미딘 화합물 |
| JP2013032290A (ja) | 2009-11-20 | 2013-02-14 | Dainippon Sumitomo Pharma Co Ltd | 新規縮合ピリミジン誘導体 |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| WO2012067269A1 (en) | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Aminoalkoxyphenyl compounds and their use in the treatment of disease |
| WO2012066335A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Phenol compounds als toll -like receptor 7 agonists |
| MY170941A (en) | 2011-04-08 | 2019-09-19 | Janssen Sciences Ireland Uc | Pyrimidine derivatives for the treatment of viral infections |
| BR112013029537B1 (pt) | 2011-05-18 | 2020-06-30 | Janssen Sciences Ireland Uc | derivados de quinazolina, seu uso no tratamento de infecções virais e outras doenças e composição farmacêutica que os compreende |
| IN2014MN00862A (enExample) | 2011-11-09 | 2015-04-17 | Janssen R & D Ireland | |
| SG11201404743TA (en) | 2012-02-08 | 2014-09-26 | Janssen R & D Ireland | Piperidino-pyrimidine derivatives for the treatment of viral infections |
| EP2841428B1 (en) | 2012-04-24 | 2018-08-22 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| AU2013288600B2 (en) | 2012-07-13 | 2017-06-29 | Janssen Sciences Ireland Uc | Macrocyclic purines for the treatment of viral infections |
| WO2014023813A1 (en) | 2012-08-10 | 2014-02-13 | Janssen R&D Ireland | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases |
| EP2712866A1 (en) | 2012-10-01 | 2014-04-02 | Centre National de la Recherche Scientifique (CNRS) | 1,2,4-triazine derivatives for the treatment of viral infections |
| UA118018C2 (uk) | 2012-10-05 | 2018-11-12 | ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі | Ациламінопіримідинові похідні для лікування вірусних інфекцій та інших захворювань |
| MX365114B (es) | 2012-10-10 | 2019-05-23 | Janssen Sciences Ireland Uc | Derivados pirrolo[3,2-d]pirimidinicos para el tratamiento de infecciones viricas y otras enfermedades. |
| MY171115A (en) | 2012-11-16 | 2019-09-26 | Janssen Sciences Ireland Uc | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
| UA118751C2 (uk) | 2013-02-21 | 2019-03-11 | ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі | Похідні 2-амінопіримідину для лікування вірусних інфекцій |
| ES2625456T3 (es) | 2013-03-29 | 2017-07-19 | Janssen Sciences Ireland Uc | Desazapurinonas macrocíclicas para el tratamiento de infecciones víricas |
| EP3027624B1 (en) | 2013-07-30 | 2018-09-12 | Janssen Sciences Ireland UC | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections |
| EP3166938A4 (en) | 2014-07-11 | 2018-01-17 | Northwestern University | 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase |
-
2012
- 2012-11-08 IN IN862MUN2014 patent/IN2014MN00862A/en unknown
- 2012-11-08 HU HUE12784574A patent/HUE040541T2/hu unknown
- 2012-11-08 CN CN201280054925.3A patent/CN104066733A/zh active Pending
- 2012-11-08 HR HRP20181497TT patent/HRP20181497T1/hr unknown
- 2012-11-08 SI SI201231396T patent/SI2776439T1/sl unknown
- 2012-11-08 AU AU2012334127A patent/AU2012334127B2/en not_active Ceased
- 2012-11-08 CN CN201610878913.2A patent/CN107011346B/zh not_active Expired - Fee Related
- 2012-11-08 KR KR1020147012325A patent/KR102025276B1/ko not_active Expired - Fee Related
- 2012-11-08 PH PH1/2014/501045A patent/PH12014501045B1/en unknown
- 2012-11-08 MY MYPI2014001348A patent/MY173422A/en unknown
- 2012-11-08 RS RS20181163A patent/RS57851B1/sr unknown
- 2012-11-08 SG SG11201401244TA patent/SG11201401244TA/en unknown
- 2012-11-08 SM SM20180514T patent/SMT201800514T1/it unknown
- 2012-11-08 BR BR112014011162A patent/BR112014011162A2/pt not_active IP Right Cessation
- 2012-11-08 PT PT12784574T patent/PT2776439T/pt unknown
- 2012-11-08 BR BR122019020718-6A patent/BR122019020718B1/pt active IP Right Grant
- 2012-11-08 ES ES12784574.1T patent/ES2690082T3/es active Active
- 2012-11-08 WO PCT/EP2012/072090 patent/WO2013068438A1/en not_active Ceased
- 2012-11-08 MX MX2014005619A patent/MX347596B/es active IP Right Grant
- 2012-11-08 JP JP2014540449A patent/JP6349256B2/ja active Active
- 2012-11-08 EA EA201991767A patent/EA036645B1/ru unknown
- 2012-11-08 EA EA201490947A patent/EA033830B1/ru unknown
- 2012-11-08 LT LTEP12784574.1T patent/LT2776439T/lt unknown
- 2012-11-08 US US14/357,495 patent/US9556176B2/en not_active Expired - Fee Related
- 2012-11-08 DK DK12784574.1T patent/DK2776439T3/en active
- 2012-11-08 PL PL12784574T patent/PL2776439T3/pl unknown
- 2012-11-08 CA CA2850448A patent/CA2850448C/en active Active
- 2012-11-08 UA UAA201403138A patent/UA116083C2/uk unknown
- 2012-11-08 EP EP12784574.1A patent/EP2776439B1/en active Active
-
2014
- 2014-04-10 IL IL232046A patent/IL232046A/en active IP Right Grant
- 2014-05-08 CL CL2014001205A patent/CL2014001205A1/es unknown
-
2017
- 2017-01-30 US US15/420,045 patent/US10280167B2/en active Active
-
2018
- 2018-10-03 CY CY20181101018T patent/CY1121452T1/el unknown
-
2019
- 2019-05-06 US US16/404,601 patent/US11104678B2/en not_active Expired - Fee Related
-
2021
- 2021-08-30 US US17/460,922 patent/US20220235052A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014001205A1 (es) | Compuestos derivados de purina, sus sales y solvatos farmaceuticamente aceptables; composicion farmaceutica que los comprende, util para el tratamiento de un trastorno en el que interviene la modulacion de tlr7, tal como infecciones viricas, trastornos inmunitarios o inflamatorios. | |
| CL2015000080A1 (es) | Compuestos derivados de purinas macrociclicas y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de un trastorno en el que interviene la modulacion de tlr7, tales como infecciones viricas, trastornos inmunitarios o inflamatorios. | |
| CL2015001265A1 (es) | Compuestos derivados de 2-aminoquinazolina sustituidos; composicion farmaceutica que los comprende, util para el tratamiento de un trastorno en el que interviene la modulacion de tlr7 y/o tlr8 tal como infecciones viricas. | |
| CL2014000566A1 (es) | Compuestos derivados de pirrolopirimidina y purina, y sus sales farmaceuticamente aceptables; composicion farmaceutica que los comprende, util para el tratamiento del crecimiento celular anormal, tal como cancer. | |
| CL2015002891A1 (es) | Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales. | |
| CL2014000746A1 (es) | Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer. | |
| CL2014001855A1 (es) | Compuestos derivados de imidazopirrolidinona o sus sales, formas cristalinas; composicion farmaceutica que los comprende; y su uso para el tratamiento de un trastorno o enfermedad mediada por la actividad de mdm2 y/o mdm4 tales como enfermedades proliferativas, especialmente cancer. | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| ECSP18048718A (es) | Imidazolilimidazoles condensados como compuestos antivirales | |
| CL2013003313A1 (es) | Compuestos derivados de 2,4-diaminoquinazolinas, sales o solvatos farmacéuticamente aceptables; composición farmacéutica que los comprende; y uso en el tratamiento de un trastorno en el que interviene la modulación de tlr7 y/o tlr8. | |
| CL2013002877A1 (es) | Compuestos derivados de 2-aminopirimidina o una de sus sales, tautomeros o solvatos farmaceuticamente aceptables, moduladores de los receptores tlr7 y/o tlr8; composicion farmaceutica que los comprende, utiles para el tratamiento de infecciones viricas tales como vhb o vhc | |
| CL2015000408A1 (es) | Compuestos derivados de pirazolo[4,3-d]pirimidina y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de enfermedades alergicas, inflamatorias, infecciosas o cancer. | |
| CL2014001793A1 (es) | Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
| CL2014002412A1 (es) | Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras. | |
| CL2014000642A1 (es) | Compuestos derivados de indazol-3-carboxamidas, como inhibidores de la ruta de señalizacion de wnt/b-catenina; composicion farmaceutica que los comprende; y su uso para el tratamiento de cancer, artritis reumatoide, infecciones micoticas y viricas, enfermedad de parkinson, un trastorno fibrotico, entre otras enfermedades. | |
| UY35675A (es) | Derivados sustituidos de quinazolin-4-ona | |
| CL2015000787A1 (es) | Derivados de 1,2,4-triazina para el tratamiento de infecciones virales. | |
| CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
| ECSP14013199A (es) | Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio | |
| CL2013003051A1 (es) | Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio | |
| CO2017001884A2 (es) | Polimorfos de selinexor | |
| CL2015001377A1 (es) | Inhbibidores de bmi-1 primidinas sustituidas inversas | |
| UY34545A (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios. | |
| CL2015001279A1 (es) | Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras. | |
| GT201600269A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble |